SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Morgan Stanley Asia Singapore sells 17.32 lakh shares of Aurobindo Pharma: Report

31 May 2014 Evaluate

Morgan Stanley Asia Singapore has sold 17.32 lakh shares of Aurobindo Pharma through the open market route. The shares were sold on an average price of Rs 669.92 valuing the transaction at Rs 116.06 crore. On the other hand, Abu Dhabi Investment Authority has bought 14.75 shares in the company for an average price of Rs 670.51, through open market route valuing the transaction at Rs 98.95 crore.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1379.90 -5.75 (-0.41%)
20-Apr-2026 11:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.50
Dr. Reddys Lab 1237.75
Cipla 1238.15
Zydus Lifesciences 941.45
Lupin 2330.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×